Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Kiniksa Pharmaceuticals Ltd
PP&E Gross
Kiniksa Pharmaceuticals Ltd
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
PP&E Gross
$11.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
Kiniksa Pharmaceuticals Ltd
Glance View
Founded with a vision to tackle some of the most challenging inflammatory and autoimmune diseases, Kiniksa Pharmaceuticals Ltd. emerged as a nimble player in the competitive biotechnology landscape. This company, leveraging the vast potential of advanced scientific knowledge and biotechnological breakthroughs, focuses on developing and commercializing innovative therapies. Its portfolio is strategically designed to address unmet needs in the treatment of debilitating diseases. Central to its operations is a robust pipeline of monoclonal antibodies and cutting-edge biologics that promise new hope for patients. Guided by a commitment to rigorous clinical development and strategic collaborations, Kiniksa seeks to navigate the complexities of regulatory pathways, bringing its specialized therapeutic solutions to global markets. The financial engine of Kiniksa's ambitious journey is fueled by a combination of strategic partnerships, successful licensing agreements, and prudent capital allocation. By forging alliances with larger pharmaceutical firms, the company gains access to invaluable resources and distribution channels while minimizing its financial risks. This collaborative approach not only expedites the development process but also amplifies market reach, ensuring that novel treatments are accessible to the patients who need them. Revenue streams are bolstered through a mix of upfront payments, milestone achievements, and royalties as its therapies progress through stages of clinical trials and, finally, into the hands of healthcare providers. This business model, one that intertwines innovation with strategic alliances, is designed to sustain growth, balance risk, and ultimately fulfill the company's mission of transforming patients’ lives.
See Also
What is Kiniksa Pharmaceuticals Ltd's PP&E Gross?
PP&E Gross
11.7m
USD
Based on the financial report for Sep 30, 2024, Kiniksa Pharmaceuticals Ltd's PP&E Gross amounts to 11.7m USD.
What is Kiniksa Pharmaceuticals Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
6%
Over the last year, the PP&E Gross growth was -14%. The average annual PP&E Gross growth rates for Kiniksa Pharmaceuticals Ltd have been 8% over the past three years , 6% over the past five years .